Voyageur Pharmaceuticals Strengthens Scientific Team by Adding Dr. Brian Mueller as Director of Chemistry and Secures Exclusive Ownership of Iodine Extraction Technology
Voyageur Pivot: Secures Direct Ownership of Iodine Tech While Ditching Previous Partner Amidst Working Capital Deficit
The news release dated January 12, 2026, announces that Voyageur Pharmaceuticals (VM) has acquired 100% ownership of the "Mueller Process," a proprietary iodine extraction technology, from Dr. Brian Mueller. Dr. Mueller has subsequently been appointed as Director of Chemistry. This acquisition replaces the previously announced collaboration with Altillion Inc. (dated June 23, 2025), which has now been terminated. The acquired technology reportedly achieved 90% iodine extraction yields and 99.5% purity at bench scale. Management claims this process could allow VM to bypass the iodine flake stage and move directly to creating Active Pharmaceutical Ingredients (API) for contrast agents.
This news is material as it marks a significant strategic pivot from a third-party technology license (Altillion) to full intellectual property (IP) ownership. - Positive Impact: Owning the IP 100% eliminates future licensing disputes and gives VM control over its "from the earth to the bottle" vertical integration strategy. The addition of Dr. Mueller provides in-house expertise. - Negative Impact: The termination of the Altillion agreement, which was the cornerstone of the 2025 iodine strategy, suggests the previous plan was either technically flawed or commercially unviable. - Critical Caveat: The 90% yield and 99.5% purity claims are based on "initial bench scale testing" and have not been independently verified. Third-party evaluation is not expected until later in 2026.
Voyageur Pharmaceuticals is developing a vertically integrated supply chain for radiology contrast media (barium and iodine). - Flagship Project: Frances Creek Barium Project (British Columbia). It contains a high-grade natural barite resource with a 2022 PEA NPV of $344 million. - Secondary Project: Iodine extraction in the Anadarko Basin (Oklahoma) and lithium/iodine exploration in the Paradox Basin (Utah). - Business Model: Transitioning from a junior explorer to a pharmaceutical manufacturer by using its own mineral resources to produce low-cost contrast agents.